Association between US state medical cannabis laws and opioid prescribing in the medicare part D population

JAMA Internal Medicine

Volumn 178, Issue 5, 2018, Pages 667-673

  Bradford, Ashley C ^a   Bradford, W David ^a   Abraham, Amanda ^a   Adams, Grace Bagwell ^b  

^a UNIVERSITY OF GEORGIA   (United States)

^b UNIVERSITY OF GEORGIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FENTANYL; HYDROCODONE; MEDICAL CANNABIS; METHADONE; MORPHINE; OPIATE; OXYCODONE; CANNABIS; NARCOTIC ANALGESIC AGENT;

ARTICLE; ASSOCIATION; HUMAN; LAW; MAJOR CLINICAL STUDY; MEDICARE; OUTCOME ASSESSMENT; POPULATION; PRESCRIPTION; PRIORITY JOURNAL; SECONDARY ANALYSIS; UNITED STATES; AGED; CLINICAL PRACTICE; DRUG LEGISLATION; FEMALE; GOVERNMENT; LONGITUDINAL STUDY; MALE; STATISTICS AND NUMERICAL DATA; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANALGESICS, OPIOID; CANNABIS; FEMALE; HUMANS; LEGISLATION, DRUG; LONGITUDINAL STUDIES; MALE; MEDICAL MARIJUANA; MEDICARE PART D; PRACTICE PATTERNS, PHYSICIANS'; STATE GOVERNMENT; UNITED STATES;

EID: 85045044184     PISSN: 21686106     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamainternmed.2018.0266     Document Type: Article

References (38)

1. Compton WM, Volkow ND. Major increases in opioid analgesic abuse in the United States: concerns and strategies. Drug Alcohol Depend. 2006;81(2):103-107.
2. Rosenblum A, Marsch LA, Joseph H, Portenoy RK. Opioids and the treatment of chronic pain: controversies, current status, and future directions. Exp Clin Psychopharmacol. 2008;16(5):405-416.
3. Merboth MK, Barnason S. Managing pain: the fifth vital sign. Nurs Clin North Am. 2000;35(2):375-383.
4. Tompkins DA, Hobelmann JG, Compton P. Providing chronic pain management in the "fifth vital sign" era: historical and treatment perspectives on a modern-day medical dilemma. Drug Alcohol Depend. 2017;173(suppl 1):S11-S21.
5. Mularski RA, White-Chu F, Overbay D, Miller L, Asch SM, Ganzini L. Measuring pain as the 5th vital sign does not improve quality of pain management. J Gen Intern Med. 2006;21(6):607-612.
6. Council NR. Relieving Pain in America: A Blueprint for Transforming Prevention, Care. Education, and ResearchWashington. DC: The National Academies Press; 2011.
7. Hedegaard H, Warner M, Miniño AM. Drug overdose deaths in the United States, 1999-2015. NCHS Data Brief. 2017;(273):1-8.
8. Okie S. A flood of opioids, a rising tide of deaths. N Engl J Med. 2010;363(21):1981-1985.
9. Powell D, Pacula RL, Taylor E. How Increasing Medical Access to Opioids Contributes to the Opioid Epidemic: Evidence From Medicare Part D. Cambridge, MA: National Bureau of Economic Research; 2015.
10. Centers for Disease Control and Prevention (CDC). CDC grand rounds: prescription drug overdoses-a U.S. Epidemic. MMWR Morb Mortal Wkly Rep. 2012;61(1):10-13.
11. Manchikanti L, Standiford H Fellows B, et al. Opioid epidemic in the United States. Pain Physician. 2012;15:2150-1149.
12. Maier SL, Mannes S, Koppenhofer EL. The implications of marijuana decriminalization and legalization on crime in the United States. Contemp Drug Probl. 2017;44(2):125-146. Doi:10.1177/0091450917708790
13. Klieger SB, Gutman A, Allen L, Pacula RL, Ibrahim JK, Burris S. Mapping medical marijuana: state laws regulating patients, product safety, supply chains and dispensaries, 2017. Addiction. 2017;112(12):2206-2216.
14. Hoffmann DE, Weber E. Medical marijuana and the law. N Engl J Med. 2010;362(16):1453-1457.
15. Wen H, Hockenberry JM, Cummings JR. The effect of medical marijuana laws on adolescent and adult use of marijuana, alcohol, and other substances. J Health Econ. 2015;42:64-80.
16. Klofas J, Letteney K. The Social and Legal Effects of Medical Marijuana: State Legislation and Rules.Working Paper, Center for Public Safety Initiatives, Rochester Institute of Technology; Rochester, NY; 2012.
17. Ellis RJ, ToperoffW, Vaida F, et al. Smoked medicinal cannabis for neuropathic pain in HIV: a randomized, crossover clinical trial. Neuropsychopharmacology. 2009;34(3):672-680.
18. Hill KP. Medical marijuana for treatment of chronic pain and other medical and psychiatric problems: a clinical review. JAMA. 2015;313(24): 2474-2483.
19. Lynch ME, Ware MA. Cannabinoids for the treatment of chronic non-cancer pain: an updated systematic review of randomized controlled trials. J Neuroimmune Pharmacol. 2015;10(2):293-301.
20. Rog DJ, Nurmikko TJ, Friede T, Young CA. Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis. Neurology. 2005;65(6):812-819.
21. Savage SR, Romero-Sandoval A, Schatman M, et al. Cannabis in pain treatment: clinical and research considerations. J Pain. 2016;17(6):654-668.
22. Ware MA, Wang T, Shapiro S, Collet J-P; COMPASS Study Team. Cannabis for the management of pain: assessment of safety study (COMPASS). J Pain. 2015;16(12):1233-1242.
23. Ware MA, Wang T, Shapiro S, et al. Smoked cannabis for chronic neuropathic pain: a randomized controlled trial. CMAJ. 2010;182(14): E694-E701.
24. National Academies of Sciences, Engineering, and Medicine. The Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for Research.Washington, DC: National Academies Press; 2017.
25. Kaskie B, Ayyagari P, Milavetz G, Shane D, Arora K. The increasing use of cannabis among older Americans: a public health crisis or viable policy alternative? Gerontologist. 2017;57(6):1166-1172.
26. Bradford AC, Bradford WD. Medical marijuana laws reduce prescription medication use in Medicare Part D. Health Aff (Millwood). 2016;35(7): 1230-1236.
27. Bradford AC, Bradford WD. Medical marijuana laws may be associated with a decline in the number of prescriptions for Medicaid enrollees. Health Affairs (Millwood). 2017;36(5):945-951.
28. Pacula RL, Powell D, Heaton P, Sevigny EL. Assessing the effects of medical marijuana laws on marijuana use: the devil is in the details. J Policy Anal Manage. 2015;34(1):7-31.
29. National Institute on Drug Abuse. What is medical marijuana? 2017 https://www.drugabuse .gov/publications/drugfacts/marijuana-medicine. Accessed September 1 2017.
30. MPP. State-by-State Medical Marijuana Laws: How to Remove the Threat of Arrest 2015. Washington, DC: Marijuana Policy Project; 2016.
31. ProCon.org. 29 Legal Medical Marijuana States and DC: Laws, Fees, and Possession Limits. 2017 https://medicalmarijuana.procon.org/view.resource .php?resourceID=000881 Accessed June 5 2017.
32. O'Keefe K. State medical marijuana implementation and federal policy. J Health Care Law Policy. 2013;16(1):39-58.
33. Pacula RL, Hunt P, Boustead A.Words can be deceiving: a review of variation among legally effective medical marijuana laws in the United States. J Drug Policy Anal. 2014;7(1):1-19.
34. Pacula RL, Sevigny EL. Natural experiments in a complex and dynamic environment: the need for a measured assessment of the evidence. J Policy Anal Manage. 2014;33(1):232-235.
35. Bachhuber MA, Saloner B, Cunningham CO, Barry CL. Medical cannabis laws and opioid analgesic overdose mortality in the United States, 1999-2010. JAMA Intern Med. 2014;174(10):1668-1673.
36. Abrams DI, Couey P, Shade SB, Kelly ME, Benowitz NL. Cannabinoid-opioid interaction in chronic pain. Clin Pharmacol Ther. 2011;90(6):844-851.
37. Boehnke KF, Litinas E, Clauw DJ. Medical cannabis use is associated with decreased opiate medication use in a retrospective cross-sectional survey of patients with chronic pain. J Pain. 2016;17 (6):739-744.
38. Harris AH, Humphreys K, Finney JW. State-level relationships cannot tell us anything about individuals. Am J Public Health. 2015;105(4): e8-e8.